Preclinical studies subsequently demonstrated that PDE5 inhibitors can downregulate arginase 1 and nitric oxide synthase-2 in tumor-associated myeloid cells, leading to reduced immune suppression and increased CD8+ T-cell infiltration into tumors (10–12). Here, PDE5A is linked to neoplasm.